1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Viking’s Phase IIb NASH Data Provide Across-The-Board Success

 
• By Joseph Haas

Competing with Madrigal in the THRβ agonist class in non-alcoholic steatohepatitis, Viking’s VK2809 reports stronger efficacy and better safety and tolerability than resmetirom at that stage.

Archer
Viking's NASH candidate hits multiple targets in Phase IIb study • Source: Shutterstock

Madrigal Pharmaceuticals, Inc. will presumably hold a significant lead on the market for its THRβ agonist resmetirom (MDGL-3196), which it plans to file for US approval in non-alcoholic steatohepatitis this quarter, but Phase IIb data reported on 16 May for Viking Therapeutics, Inc.’s THRβ agonist, VK2809, led to analysts calling the drug a best-in-class candidate for NASH. VK2809 hit its primary endpoint of reduction from baseline in liver fat content (LFC) at 12 weeks compared to placebo in the VOYAGE study.

Madrigal is running second to Intercept Pharmaceuticals, Inc. in the race to bring the first NASH drug therapy to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

EADV: Leo Makes A Big Leap With Eczema Drug Temtokibart Set For Phase III

 
• By Kevin Grogan

CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.

More from R&D

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.

AstraZeneca’s Fasenra RESOLUTE Failure Highlights The Limits Of Biologics In COPD

 
• By Alexandra Shimmings

AstraZeneca’s IL-5 blocker has again missed in COPD, adding to a number of disappointments for biologics in this disease. Complex biology and overlapping inflammatory pathways seem to be at the heart of the problem.

Lilly’s Orforglipron Bests Novo Rival In First Oral Head-To-Head Study

 
• By Andrew McConaghie

The company’s cardiometabolic leader Ken Custer discusses the topline ACHIEVE-3 results in diabetes and just-published full results of ATTAIN-1 in obesity of orforglipron, with a pledge to maximize access to the oral GLP-1 therapy worldwide, once approved.